Y-Mabs Therapeutics Profit Margin

Y-Mabs Therapeutics's profit margin stands at -26.03% as of June 2025. That compares with -28.44% in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of 21.34%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Y-Mabs Therapeutics reported -26.03% in profit margin versus -28.44% a year earlier — a 8.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Y-Mabs Therapeutics sits lower the Healthcare benchmark (21.34%) with a profit margin of -26.03%. That is roughly 222.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -26.03% for Y-Mabs Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Y-Mabs Therapeutics's profit margin evolved across reporting periods, while the comparison chart places YMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.